Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00159250

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658

Sponsor: Department of Health, United Kingdom

Updated 10 times since 2017 Last updated: Nov 18, 2019 Started: Oct 26, 2007 Primary completion: Dec 31, 2008 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Duchenne Muscular Dystrophy, this trial is completed. The trial is conducted by Department of Health, United Kingdom and has accumulated 10 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 5 earlier versions

Jan 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Nov 2019 — Jan 2020 [monthly]

Completed PHASE1_PHASE2
May 2019 — Nov 2019 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — May 2019 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Department of Health, United Kingdom
Imperial College London
Sarepta Therapeutics, Inc.

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom